维堡人群筛查计划(VISP)对67岁人群心血管疾病的相关性:按性别分层的参与率、患病率及启动心血管药物比例
丹麦维堡自2014年起邀请所有67岁人群参与腹主动脉瘤、外周动脉疾病、颈动脉斑块、高血压、心脏病和2型糖尿病筛查。截至2019年8月共邀请5505人,参与率83.7%且无性别差异;男性筛查检出各项疾病患病率均显著高于女性,但两性启动预防性药物比例相近。
要点
- 参与率83.7%,无性别差异,提示公众对心血管筛查的接受度较好。
- 男性筛查检出AAA、PAD、颈动脉斑块、心律失常、血压≥160/100 mmHg及HbA1c≥48 mmol/mol的患病率均显著高于女性。
- 筛查前未知比例以AAA(95.4%)和PAD(87.5%)最高;检出AAA、PAD和/或颈动脉斑块者中,413人(25.5%)启动抗血小板治疗,347人(21.4%)启动降脂治疗。
核心结论
- 参与率信号显示公众对参加心血管筛查的接受度;男性筛查检出疾病多于女性,但两性启动预防性药物的频率相同;需要按性别进行成本效果随访。
研究设计与样本
- 横断面队列研究,自2014年起邀请丹麦维堡所有67岁人群参与AAA、PAD、颈动脉斑块、高血压、心脏病和2型糖尿病筛查。
- 截至2019年8月共邀请5505人,其中前4826名受邀者有注册登记数据可用。
- 将筛查数据与注册登记数据结合,以估计筛查前未知的检出疾病。
主要发现
- 参与率为83.7%,无性别差异。
- 女性与男性相比,筛查检出患病率分别为:AAA 5例(0.3%) vs 38例(1.9%)(p < .001);PAD 90例(4.5%) vs 134例(6.6%)(p = .011);颈动脉斑块641例(31.8%) vs 907例(44.8%)(p < .001);心律失常26例(1.4%) vs 77例(4.2%)(p < .001);血压≥160/100 mmHg 277例(13.8%) vs 346例(17.1%)(p = .004);HbA1c≥48 mmol/mol 155例(7.7%) vs 198例(9.8%)(p = .019)。
- 筛查前未知比例:AAA为95.4%,PAD为87.5%。
- 检出AAA、PAD和/或颈动脉斑块者共1623例(40.2%),其中470例(29.0%)筛查前已接受抗血小板治疗,743例(45.8%)已接受降脂治疗;413例(25.5%)启动抗血小板治疗,347例(21.4%)启动降脂治疗。
- 多变量分析中仅吸烟与所有血管疾病显著相关:当前吸烟的比值比(OR)为AAA 8.11(95%CI 2.27 - 28.97)、PAD 5.60(95%CI 3.61 - 8.67)、颈动脉斑块3.64(95%CI 2.95 - 4.47)。
关键数值与推荐
- 筛查检出AAA、PAD和/或颈动脉斑块者被推荐接受心血管预防治疗。
- 筛查项目包括AAA、PAD、颈动脉斑块、高血压、心脏病和2型糖尿病。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report sex specific overall attendance rate, prevalence of screen detected cardiovascular conditions, proportion of unknown conditions before screening, and proportion initiating prophylactic medicine among 67 year olds in Denmark. DESIGN: Cross sectional cohort study. METHODS: Since 2014, all 67 year olds in Viborg, Denmark, have been invited to screening for abdominal aortic aneurysm (AAA), peripheral arterial disease (PAD), carotid plaque (CP), hypertension, cardiac disease, and type 2 diabetes. Individuals with AAA, PAD, and or CP are recommended cardiovascular prophylaxis. Combining data with registries has facilitated estimation of unknown screen detected conditions. Up to August 2019, 5 505 had been invited; registry data were available for the first 4 826 who were invited. RESULTS: The attendance rate was 83.7%, without sex difference. Screen detected prevalence was significantly lower among women than men: AAA, 5 (0.3%) vs. 38 (1.9%) (p < .001); PAD, 90 (4.5%) vs. 134 (6.6%) (p = .011); CP, 641 (31.8%) vs. 907 (44.8%) (p < .001); arrhythmia, 26 (1.4%) vs. 77 (4.2%) (p < .001); blood pressure ≥ 160/100 mmHg, 277 (13.8%) vs. 346 (17.1%) (p = .004); and HbA1c ≥ 48 mmol/mol, 155 (7.7%) vs. 198 (9.8%) (p = .019), respectively. Pre-screening proportions of unknown conditions were particularly high for AAA (95.4%) and PAD (87.5%). AAA, PAD, and or CP were found in 1 623 (40.2%), of whom 470 (29.0%) received pre-screening antiplatelets and 743 (45.8%) lipid lowering therapy. Furthermore, 413 (25.5%) started antiplatelet therapy and 347 (21.4%) started lipid lowering therapy. Only smoking was significantly associated with all vascular conditions in multivariable analysis: odds ratios (ORs) for current smoking were AAA 8.11 (95% CI 2.27 - 28.97), PAD 5.60 (95% CI 3.61 - 8.67) and CP 3.64 (95% CI 2.95 - 4.47). CONCLUSION: The attendance rate signals public acceptability for attending cardiovascular screening. Men had more screen detected conditions than women, but prophylactic medicine was started equally frequently in both sexes. Sex specific cost effectiveness follow up is warranted.
引用
- Dahl M, Lindholt J, Søgaard R, et al. Relevance of the Viborg Population Based Screening Programme (VISP) for Cardiovascular Conditions Among 67 Year Olds: Attendance Rate, Prevalence, and Proportion of Initiated Cardiovascular Medicines Stratified By Sex. Eur J Vasc Endovasc Surg. 2023. PMID: 36931553. doi:10.1016/j.ejvs.2023.03.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。